Amedisys (NASDAQ: AMED) reported Q3 EPS of $0.98, $0.10 worse than the analyst estimate of $1.08. Revenue for the quarter came in at $556.24 million versus the consensus estimate of $560.59 million.

For earnings history and earnings-related data on Amedisys (AMED) click here.